Novartis, every mention
20 scenes, the whole family · ← back to Novartis
tap a year for its mentions
every year anyone Vas Narasimhan 30Jorge Conde 15Sonal Chokshi 5Koki Hirasaki 4Safi Bahcall 1Matei Zaharia 1Kristen Fortney 1Jonathan Lim 1
Verbatim, from the transcripts: the passages where Novartis comes up
Biotech CEO on where we are in the fight to cure cancer
- ▶ 17:58 Jonathan Lim Uh, RAS targeting agents, and then we sort of brought in a number of assets, and we went public, as you'll recall, around the ERK targeting program, and then we, uh, brought in, uh, Naporafinib from Novartis, and that's a really exciting…
Big Ideas in 2024: Programming Medicine’s Final Frontier with Jorge Conde
- ▶ 21:23 Jorge Conde You know, in the case of treating a baby that had, you know, something like somatic muscular atrophy that would have otherwise died, a one and done gene therapy, uh, from Novartis, this is a, a therapy that's worth about, it's cost about…
a16z Podcast | Incenting Innovation Inside, Loonshots to Moonshots
- ▶ 0:42 Sonal Chokshi By the way, you can find other episodes touching on some of these themes from different angles, including with former Stanford president John Hennessy on the transition of ideas from academia to startups, and with CEO of Novartis…
- ▶ 4:20 Safi Bahcall So the parallel, China, India, and the Islamic empires were a lot like the Merck, Pfizer, and Novartis of today.
What’s with All the Bio M&A in 2019?: A Quick Take
- ▶ 5:24 Koki Hirasaki The investment, uh, sorry, this is CEO Voss Narsenhan of Novartis. 2 times in the scene
- ▶ 8:23 Koki Hirasaki So, uh, when we met with Voss, he, he talked about, um, of access, you know, again, being a platform, but, but also giving Novartis, uh, scalable manufacturing in the gene therapy space.
- ▶ 19:47 Koki Hirasaki Uh, they, uh, kept the U.S. rights and, um, uh, outlicensed the ex-U.S. rights to Novartis, which is actually a weird entanglement now because, uh, the, the two, uh, Basel-based rivals, uh, are sharing an asset.
a16z Podcast | The Science and Business of Innovative Medicines
- ▶ 0:12 Sonal Chokshi So in this conversation, A, Six and Z by our general partners, Jorge Conde and Vijay Pandey, join me to interview special guest, Voss Neurosimhan, the CEO of Novartis, which is one of the largest healthcare and pharmaceutical companies in… 2 times in the scene
- ▶ 1:10 Vas Narasimhan If you think about cardiovascular disease, we've been in it 40, 50 years. 9 times in the scene
- ▶ 5:18 Vas Narasimhan We've actually been fortunate at our company.
- ▶ 12:04 Vas Narasimhan So, uh, you know, if you look overall at Novartis generics, you know, from a sales standpoint and value standpoint, um, is, is a small portion of the company, but you look at a volume standpoint, it's the biggest part of access. 6 times in the scene
- ▶ 13:33 Jorge Conde You know, you talk about Novartis becoming a medicines company using data science and novel platforms. 2 times in the scene
- ▶ 17:10 Vas Narasimhan I think right now in this, um, nascent phase that we're in, uh, we believe we need to just own it because the launches are so important that we can't afford there to be a lot of experimentation and not being, not really owning the supply… 8 times in the scene
- ▶ 25:25 Vas Narasimhan So one that, that, uh, our company is working on is RNA interference to impact a, a factor that's really a big part of heart disease. 2 times in the scene
- ▶ 36:06 Sonal Chokshi I'm very curious from your take as a head of Novartis, like where do you see the strongest applications of AI and ML? 2 times in the scene
- ▶ 45:31 Vas Narasimhan Actually here in the Bay Area, we have a center called the Biome. 4 times in the scene
- ▶ 49:13 Jorge Conde I obviously see a ton of benefit in partnering with Novartis, um, access to data that doesn't exist elsewhere, um, obviously validation in my approach and my technology, etc. 8 times in the scene
- ▶ 53:59 Jorge Conde And I think that is one of the most difficult things that I would imagine that an innovative company at the scale at which Novartis operates has to always find that balance between. 4 times in the scene
a16z Podcast | A Conversation With the Inventor of Spark
- ▶ 8:28 Matei Zaharia So, so some of the other highlights, for example, included, uh, Netflix, uh, Capital One, uh, at previous summits, we also had, uh, Goldman Sachs and, and Novartis in the biotech.
Extending Human Lifespan
- ▶ 4:37 Kristen Fortney So there's a company, Restore Bio, just spun out of Novartis a year ago, IPO'd earlier this year, that's taken this drug, um, into humans.